Idiopathic Membranous Nephropathy Market to Reach USD 1,000 Million by 2036 at 0.4% CAGR Across the 7MM | DelveInsight

DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast 2036" report delivers an in-depth understanding of the Idiopathic Membranous Nephropathy, historical and forecasted epidemiology and the Idiopathic Membranous Nephropathy Market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Idiopathic Membranous Nephropathy Market Report @ https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from Idiopathic Membranous Nephropathy Market Report
• In July 2026, Biogen announced result of An Open-Label, Multicenter, Randomized Phase 3 Study Evaluating the Efficacy and Safety of Felzartamab in Participants With Primary Membranous Nephropathy (PMN) [PROMINENT].
• In July 2026, Vertex Pharmaceuticals Incorporated announced result of A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy.
• In July 2026, Climb Bio, Inc. announced result of A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN).
• In January 2026, the EMA granted Priority Medicines (PRIME) designation to povetacicept for primary membranous nephropathy.
• The Idiopathic Membranous Nephropathy market size in the 7MM was found to be approximately USD 130 million in 2025 and is projected to reach USD 1,000 million by 2036, growing at a CAGR of 0.4% over the forecast period.
• In 2025, the United States held the largest market share for Idiopathic Membranous Nephropathy among the 7MM, accounting for approximately 60% of the total market.
• In 2025, the total market size of Idiopathic Membranous Nephropathy in the US was approximately USD 85 million.
• In the 7MM, the total number of prevalent cases of Idiopathic Membranous Nephropathy was nearly 89,000 in 2025, and the US accounted for the highest diagnosed prevalent cases, with around 35,000 cases.
• Among EU4 and the UK, Germany had the highest prevalent population with 6,000 cases, followed by the UK with 5,000 cases, while France had the lowest prevalent population of 4,000 cases in 2022.
• The total treated cases in the US were 35,000 in 2025 and are expected to increase to 37,000 by 2036, while total treated cases across the 7MM were approximately 45,000 in 2025.
• The Idiopathic Membranous Nephropathy Companies include Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., among others.
• Promising Idiopathic Membranous Nephropathy Therapies include SNP-ACTH (1-39), GAZYVA (Obinutuzumab), MOR202 (felzartamab), BRUKINSA (Zanubrutinib), among others.

Get a Free sample for the Idiopathic Membranous Nephropathy Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is Idiopathic Membranous Nephropathy?
Membranous nephropathy (MN) is a rare immune-mediated glomerular disorder marked by podocyte injury that increases protein permeability, leading to proteinuria, hypoalbuminemia, and edema characteristic of nephrotic syndrome. It is the leading cause of nephrotic syndrome in Caucasian adults (approximately 30%), predominantly affecting men aged 30-50 years and occurring infrequently in children. The disease is driven by in situ formation of subepithelial immune complexes along the glomerular basement membrane, triggering complement activation and resulting in capillary wall thickening, structural damage, and impaired filtration without significant inflammation. Key antigens in primary MN include PLA2R, THSD7A, NELL-1, and Sema3B. MN is clinically heterogeneous: one-third of patients achieve spontaneous remission, one-third remain stable, and one-third progress, with up to half developing end-stage renal disease over time. It presents insidiously with edema, foamy urine, hyperlipidemia, fatigue, and hypertension, and is defined histologically by subepithelial deposits and characteristic basement membrane "spikes."

Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ https://www.delveinsight.com/report-store/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Idiopathic Membranous Nephropathy Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of Idiopathic Membranous Nephropathy
• Antigen-specific Cases of Idiopathic Membranous Nephropathy
• Treated Cases of Idiopathic Membranous Nephropathy

Idiopathic Membranous Nephropathy Approved Therapies
The therapeutic landscape for Idiopathic Membranous Nephropathy underscores a notable unmet need, as no therapies are currently marketed or specifically approved for this condition, with the focus primarily on evaluating emerging candidates in Phase III and Phase II stages of development.

Idiopathic Membranous Nephropathy Pipeline Analysis
• SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
Cerium has developed SNP-ACTH (1-39) Gel, a subcutaneous formulation of a synthetic porcine ACTH peptide, offering a quantifiable and consistent dose that may enhance optimization of treatment response in primary membranous nephropathy (PMN). Following regulatory discussions, the company has initiated a Phase III randomized superiority trial evaluating whether SNP-ACTH (1-39) Gel is more effective than rituximab in achieving sustained proteinuria remission as a first-line immunosuppressive therapy in moderate- to high-risk PMN patients, with patient enrollment currently underway.

• GAZYVA (Obinutuzumab): Hoffmann-La-Roche
Obinutuzumab is an anti-CD19 mab being evaluated in a Phase III study for treating pMN and is already approved for indications like lymphocytic leukemia and follicular lymphoma. A real-world retrospective study demonstrated strong efficacy in pMN, achieving high immunological (92.0%) and clinical remission rates (83.6%) with improvements in proteinuria, serum albumin, and kidney function over a median 13-month follow-up.

• MOR202 (felzartamab): Biogen
MOR202 is being evaluated in a Phase III study in adult participants with PMN, working through an antibody-dependent cell cytotoxicity mechanism of action.

Discover more about therapies set to grab major Idiopathic Membranous Nephropathy market share @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Idiopathic Membranous Nephropathy Companies
Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., among others

Idiopathic Membranous Nephropathy Market Outlook
The membranous nephropathy (MN) market is driven by a significant unmet need, as there is no curative or specifically approved therapy, with treatment largely centered on supportive care and broad immunosuppression. Current management relies on ACE inhibitors/ARBs, diuretics, and statins, while immunosuppressive agents such as calcineurin inhibitors, cyclophosphamide, and corticosteroids remain key revenue drivers despite safety concerns and relapse risks. Rituximab has emerged as a preferred first-line therapy for primary MN due to improved efficacy and sustained remission compared to cyclosporine, though in 2025 its market share tends to decrease through 2036. Real-world utilization of advanced therapies remains relatively low, highlighting gaps in treatment adoption, while ongoing research and clinical trials are focused on targeted and combination therapies such as Melanocortin receptor agonists (SNP-ACTH), Antibody-dependent cell cytotoxicity (GAZYVA), and Agammaglobulinaemia tyrosine kinase inhibitors (BRUKINSA). The launch of first-in-class therapies, improved diagnosis, and rising disease awareness are expected to drive steady growth in the 7MM Idiopathic Membranous Nephropathy market from 2022-2036.

Scope of the Idiopathic Membranous Nephropathy Market Report
• Study Period: 2022-2036
• Historical Year: 2022-2025
• Forecast Period: 2026-2036
• Base Year: 2026
• Coverage: 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan)
• Idiopathic Membranous Nephropathy Companies: Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., and others
• Idiopathic Membranous Nephropathy Therapies: SNP-ACTH (1-39), GAZYVA (Obinutuzumab), MOR202 (felzartamab), BRUKINSA (Zanubrutinib), and others
• Idiopathic Membranous Nephropathy Therapeutic Assessment: Idiopathic Membranous Nephropathy current marketed and emerging therapies
• Idiopathic Membranous Nephropathy Market Dynamics: Idiopathic Membranous Nephropathy market drivers and market barriers
• Competitive Intelligence Analysis: SWOT analysis, Conjoint Analysis, Market entry strategies
• Idiopathic Membranous Nephropathy Unmet Needs, KOL's views, Analyst's views, Idiopathic Membranous Nephropathy Market Access and Reimbursement

To know more about Idiopathic Membranous Nephropathy companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/idiopathic-membranous-nephropathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Emerging Drugs
12. Idiopathic Membranous Nephropathy: Seven Major Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.